levofloxacin has been researched along with perhexiline in 9 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (perhexiline) | Trials (perhexiline) | Recent Studies (post-2010) (perhexiline) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 572 | 92 | 83 |
| Protein | Taxonomy | levofloxacin (IC50) | perhexiline (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 1.4852 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 4.064 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.2942 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 3.5919 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 1.0932 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.38 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.9408 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 2.7105 | |
| D | Rattus norvegicus (Norway rat) | 7.7625 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7625 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 3.1186 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7625 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7625 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.2942 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 7.7625 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 7.7687 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.5992 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Jia, L; Sun, H | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for levofloxacin and perhexiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for levofloxacin and perhexiline
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |